UTas ePrintsBelimumab (Human Genome Sciences/Cambridge Antibody Technology/GlaxoSmithKline)CDingauthorGJonesauthorBelimumab, the lead in a series of human monoclonal antibodies against the human protein B-lymphocyte stimulator (BLyS), is under development by Human Genome Sciences, Cambridge Antibody Technology and GlaxoSmithKline for the potential treatment of autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). By January 2006, belimumab had completed phase II clinical trials in SLE and RA; a phase III clinical SLE trial is scheduled to begin later this year.320503 Clinical Pharmacology and Therapeutics2006Article

Permissions, Copyright and Authorship Statement
I grant the University of Tasmania permission to copy, store and communicate this work I declare that I either own the copyright in the work or I am submitting this work with permission of the copyright owner or under licence from the copyright owner. I declare that the metadata regarding authorship are true and correct and that it complies with the authorship requirements set down in the Joint NHMRC/AVCC Guidelines on Research and Practice.

Clicking on the deposit button indicates your agreement to these terms.